2021
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.Peer-Reviewed Original ResearchConceptsOvarian function suppressionPositive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerBreast cancerPremenopausal womenPatient preferencesPremenopausal Hormone Receptor-Positive Breast CancerAdjuvant gonadotropin‐releasing hormone analoguesHR-positive breast cancerGonadotropin-releasing hormone analogueDiscontinuation of GnRHaThird of patientsChi-square testMonthly goserelinClinical characteristicsTreatment toxicityVaginal drynessClinicopathologic characteristicsGnRH analoguesHot flashesSurgical ablationResultsA totalMedical recordsGnRHaPatient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy
Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause The Journal Of The North American Menopause Society 2021, 28: 642-649. PMID: 33534429, DOI: 10.1097/gme.0000000000001738.Peer-Reviewed Original ResearchConceptsFemale Sexual Function IndexBC survivorsSexual functionSingle-arm feasibility studyFemale Sexual Distress ScaleOverall FSFI scoreSymptoms of GSMBreast cancer survivorsPatient-reported outcomesSexual Function IndexFractional CO2 laser therapySexual Distress ScaleCO2 laser therapyFSDS-R scoresFractional CO2 laserFSFI scoreAdverse eventsGenitourinary syndromePatient demographicsVaginal drynessCancer survivorsDisease characteristicsFunction IndexLaser therapyDistress Scale
2018
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Quick A, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens J, Carpenter K, Ramaswamy B, Reinbolt R, Noonan A, VanDeusen J, Wesolowski R, Stover D, Williams N, Sardesai S, Smith K, Faubion S, Loprinzi C, Lustberg M. Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC). Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.34_suppl.202.Peer-Reviewed Original ResearchVaginal Assessment ScaleSerious adverse eventsFractional CO2 laser therapyCO2 laser therapyFemale Sexual Function IndexUrogenital Distress InventoryVaginal drynessBC survivorsBreast cancerLaser therapyStudy treatmentSingle-arm feasibility studySecondary efficacy endpointsFinal efficacy analysisSexual Function IndexER/PRFractional CO2 laser treatmentFractional CO2 laserEndocrine therapySham laserEfficacy endpointFSFI scoreAdverse eventsGenitourinary syndromePrimary efficacy
2015
Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.Peer-Reviewed Original ResearchBreast cancer survivorsAtrophic vaginitisCancer survivorsEndocrine therapySelective estrogen receptor modulatorsSystemic estrogen therapyPatient-reported symptomsEstrogen receptor modulatorsVariety of symptomsQuality of lifeVaginal moistureEstrogen therapyLifestyle modificationLocal estrogenTopical estrogenVaginal drynessGynecological examinationSurvivorship issuesGenital skinOvarian failureVaginal dischargeSystematic therapyAromatase inhibitorsReceptor modulatorsBreast cancer